Supriya Lifescience Ltd

₹ 244 1.37%
25 Nov - close price
About

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]

Key Points

Niche Offerings[1]
The Company's focus is primarily on diverse therapeutic areas and niche products offerings of 38 APIs focused on diverse therapeutic segments. They have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between Fiscal 2017 and 2021. They were among the largest exporters of Salbutamol Sulphate contributing to 31% of the API exports from India in FY 2021 in volume terms.

  • Market Cap 1,968 Cr.
  • Current Price 244
  • High / Low 602 / 231
  • Stock P/E 15.4
  • Book Value 81.0
  • Dividend Yield 0.25 %
  • ROCE 43.0 %
  • ROE 34.3 %
  • Face Value 2.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 93.1% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 45.2%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
81 132 77 148 122 181 101 112
55 65 61 70 79 106 70 84
Operating Profit 26 67 15 78 43 75 31 29
OPM % 32% 51% 20% 53% 35% 42% 31% 25%
4 2 2 3 1 4 2 3
Interest 1 1 1 1 1 1 1 1
Depreciation 5 2 2 2 3 3 3 3
Profit before tax 25 66 14 78 40 75 30 27
Tax % 36% 26% 45% 25% 1% 39% 16% 39%
Net Profit 16 49 8 58 40 46 25 17
EPS in Rs 2.14 6.63 1.06 7.96 4.93 5.74 3.14 2.09
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
184 213 278 312 391 530 516
166 191 213 213 218 316 338
Operating Profit 17 22 65 98 173 214 178
OPM % 9% 10% 23% 32% 44% 40% 34%
7 9 8 11 5 8 10
Interest 12 11 10 7 4 4 4
Depreciation 5 5 5 6 7 10 11
Profit before tax 8 14 57 96 167 207 173
Tax % 30% 40% 31% 24% 26% 27%
Net Profit 6 9 39 73 124 152 128
EPS in Rs 3.87 5.96 26.93 50.11 16.89 18.86 15.90
Dividend Payout % 0% 0% 0% 20% 3% 3%
Compounded Sales Growth
10 Years: %
5 Years: 24%
3 Years: 24%
TTM: 18%
Compounded Profit Growth
10 Years: %
5 Years: 93%
3 Years: 57%
TTM: -2%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 44%
3 Years: 45%
Last Year: 34%

Balance Sheet

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
15 15 15 15 15 16 16
Reserves 31 40 79 134 254 600 636
140 130 90 82 72 27 36
55 60 69 105 105 92 73
Total Liabilities 241 245 253 336 445 735 762
89 91 85 99 100 190 189
CWIP 36 34 35 40 79 43 74
Investments 0 0 0 0 0 0 0
117 120 133 197 267 502 498
Total Assets 241 245 253 336 445 735 762

Cash Flows

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
27 28 49 117 76 49
-27 -5 5 -25 -47 -60
-2 -20 -50 -29 -15 150
Net Cash Flow -2 3 4 62 15 139

Ratios

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 99 92 79 60 69 79
Inventory Days 113 85 77 130 206 172
Days Payable 121 112 110 130 145 91
Cash Conversion Cycle 91 64 45 61 130 160
Working Capital Days 119 97 96 49 94 132
ROCE % 14% 37% 50% 60% 43%

Shareholding Pattern

Numbers in percentages

Dec 2021 Mar 2022 Jun 2022 Sep 2022
68.24 68.24 68.24 68.24
10.30 7.13 5.99 6.79
7.90 7.73 10.33 8.88
13.56 16.90 15.44 16.09

Documents

Concalls